Corpus overview


MeSH Disease



There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page

    Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs

    Authors: Ujjwal Neogi; Kyle J. Hill; Anoop T. Ambikan; Xiao Heng; Thomas P. Quinn; Siddappa N. Byrareddy; Anders Sönnerborg; Stefan G. Sarafianos; Kamal Singh

    id:10.20944/preprints202004.0184.v1 Date: 2020-04-12 Source:

    Coronaviruses (CoVs) are positive-stranded RNA viruses that infect MESHD humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKUI1 leads to the common cold, short lasting rhinitis MESHD rhinitis HP, cough HP, sore throat and fever MESHD fever HP. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) MESHD, and the newest SARS-CoV-2 (the causative agent of COVID-19 MESHD) lead to severe and deadly diseases MESHD with mortality rates ranging between ~1 to 35% depending on factors such as age TRANS and pre-existing conditions. Despite continuous global health threats to human, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 MESHD emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.